EcoR1 Capital
Life sciences investment firm focused on identifying breakthrough biotech companies at inflection points.
EcoR1 is essentially Oleg Nodelman's biotech hedge fund masquerading as a VC firm, and that's both its strength and potential weakness. Managing over $5 billion in discretionary assets, Nodelman brings serious biotech expertise from his BVF days and sits on multiple public biotech boards. The fund clearly knows how to pick winners and has impressive returns. But don't expect traditional VC hand-holding—this is more financial engineering than startup nurturing. They're great if you need smart money that understands biotech deeply, but if you want a partner who will roll up their sleeves on board management and recruiting, look elsewhere. Their portfolio skews heavily toward later-stage, publicly traded companies, so early-stage founders should manage expectations accordingly.
- —Best for: Biotech companies needing sophisticated investors who understand drug development
- —Watch out for: More financial investor than startup partner—limited operational support
- —Known for: Deep biotech expertise and strong returns, but operates like hedge fund not traditional VC
EcoR1 Capital is a San Francisco based biotech-focused investment fund that aims to identify and evaluate innovative therapeutic solutions that can bring significant improvements to patients' lives. Drawing inspiration from the transformative power of the EcoR1 restriction enzyme in the biomedical field, they invest in biotech companies that offer promising new treatments for untreated diseases.
With over twenty years of experience in biotech investing, EcoR1 invests in companies at all stages of research and development but focuses heavily on publicly traded biotech companies. Their portfolio is dominated by public biotech names like Zymeworks, AnaptysBio, Jazz Pharmaceuticals, and Crinetics Pharmaceuticals. With 140 total investments and 76 exits, they operate more like a biotech-focused hedge fund than a traditional VC.
With over twenty years of experience in biotech investing, Nodelman was previously a portfolio manager at BVF Partners, one of the first hedge funds dedicated to the biotechnology sector. He currently serves as a Board Member for four publicly traded companies including Aktis Oncology, AnaptysBio, Zymeworks, and Galapagos. His hedge fund background shows—EcoR1 operates with impressive returns and higher concentration in top positions than typical biotech VCs.
Have a specific question about EcoR1 Capital?
Ask Bernie →